Shattuck Labs to Attend Investor Conferences Scheduled for December
Company Overview: Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics targeting TNF superfamily receptors for inflammatory and immune-mediated diseases, with a lead program, SL-325, currently in Phase 1 clinical trials.
Upcoming Conferences: The company's management, led by CEO Taylor Schreiber, will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, and the Evercore ISI 8th Annual HealthCONx Conference on December 4, 2025, featuring presentations and one-on-one meetings.
SL-325 Details: SL-325 is a potential first-in-class DR3 blocking antibody designed for a complete blockade of the DR3/TL1A pathway, showing high affinity and superior activity in preclinical studies, with a favorable safety profile in non-human primates.
Investor Relations: For more information, interested parties can visit Shattuck Labs' website or contact Andrew R. Neill, the Chief Financial Officer, for investor inquiries.
Trade with 70% Backtested Accuracy
Analyst Views on STTK
About STTK
About the author

Shattuck Labs Shares Rise After Piper Sandler Initiates Overweight Rating
- Rating Upgrade: Piper Sandler initiates coverage on Shattuck Labs (STTK) with an Overweight rating and a $15 price target, likely driving an increase in the company's stock price.
- Clinical Trial Catalysts: Analyst Yasmeen Rahimi highlights that Shattuck's lead candidate SL-325 is set to report initial Phase 1 trial results in Q2 and initiate mid-stage trials in Q3, presenting significant market opportunities for the company.
- Mechanism Validation: The mechanism of action for SL-325 has been validated by nearly eight drugs targeting TL1A, a protein that causes inflammation through interaction with the DR3 receptor, which Shattuck's candidate aims to block, providing durable inflammation protection.
- Differentiated Treatment: The analyst notes that SL-325 offers a differentiated approach to treating inflammatory bowel disease patients, expected to have a greater inhibitory effect, thereby enhancing its competitive position in the market.

Latest Rating Changes on Wall Street
- Mizuho Upgrades Applied Materials: Mizuho upgrades Applied Materials (AMAT) to Outperform from Neutral, raising the price target to $370, reflecting confidence in the semiconductor company's accelerating growth, which is expected to boost its stock price.
- Jefferies Downgrades BJ's Wholesale: Jefferies downgrades BJ's Wholesale from Buy to Hold, citing slower growth and increased risks in competitive markets, which may lead to underperformance and affect investor sentiment.
- Morgan Stanley Upgrades Johnson & Johnson: Morgan Stanley upgrades Johnson & Johnson (JNJ) to Overweight with a price target increase to $252, based on expectations of new product contributions and a higher P/E ratio, likely driving future earnings growth.
- Barclays Initiates TPG as Overweight: Barclays initiates TPG with an Overweight rating, highlighting its strong positioning for medium-term growth in a recovering capital markets environment, which is expected to attract more investor interest.






